Clinical trial
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture: A Single-Arm Prospective Study Compared to Historical Controls (STRIDE-HIP Study)
NCT07905404 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture: A Single-Arm Prospective Study Compared to Historical Controls (STRIDE-HIP Study)
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- January 5, 2027
- Completion date
- July 30, 2028
- Enrollment
- 79 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hip fractures (icd-10 72.01-72.2), post operative analgesia
Arms
As registered; 2 arms.
-
Matched Historical Controls
Historical controls will be selected at approximately a 2:1 ratio using prespecified clinical matching and propensity-score methods to improve comparability between cohorts. Historical controls will be matched on factors including age, sex, fracture type, surgery type, surgeon, ASA class, opioid-naïve status, regional anesthesia, and relevant comorbidities.
-
Suzetrigine + Standard Multimodal Analgesia
Participants undergoing operative treatment for acute hip fracture will receive suzetrigine in addition to standard-of-care multimodal analgesia
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Postoperative Opioid Consumption Rate
Total opioid analgesic administration will be converted to morphine milligram equivalents (MME). Opioid consumption will be expressed as MME per hour during the primary postoperative observation window to account for differences in duration of hospitalization. Lower MME/hour indicates lower opioid consumption.
-
Cumulative Postoperative Opioid Consumption
Total opioid analgesic administration during the primary postoperative observation window will be converted to cumulative morphine milligram equivalents (MME). Lower cumulative MME indicates lower total opioid exposure.
Lead sponsor's other trials
Beth Israel Deaconess Medical Center, most recent start first.
+562 more trials See the organization page
Similar trials
Same condition (Hip Fractures) and phase, most recent start first.
+67 more trials See the condition page